PACB
HealthcarePacific Biosciences of California, Inc. · Medical - Devices · $380M
What is Pacific Biosciences of California, Inc.?
Pacific Biosciences of California develops and manufactures long-read DNA sequencing systems aimed at resolving complex genomic challenges for researchers and clinical labs worldwide.
PacBio generates revenue by selling sequencing instruments alongside consumables — including SMRT cells, reagent kits, and binding kits — that customers repurchase with each sequencing run. The company serves genome centers, pharmaceutical companies, public health labs, and academic institutions, distributing through a direct sales force in North America and Europe and distribution partners elsewhere.
Founded in 2010 and headquartered in Menlo Park, California.
- Long-read sequencing systems (PacBio platforms)
- SMRT cell consumables
- Reagent and binding kits for sequencing workflows
Is PACB a Good Stock to Buy?
UQS Score rates PACB as Poor overall.
Among the five pillars, Risk comes in at a Neutral rating — the least concerning area of the profile. This suggests the company is not facing extreme near-term balance-sheet stress relative to its stage.
Quality, Moat, and Growth all register as Weak, while Valuation is rated Elevated — a combination that signals meaningful fundamental headwinds.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PACB pay dividends?
No — Pacific Biosciences of California, Inc. does not currently pay a dividend.
PACB does not pay a dividend. At its current stage, the company directs available capital toward research, product development, and expanding its commercial reach rather than returning cash to shareholders.
When does PACB report earnings?
Pacific Biosciences reports earnings on a quarterly cadence, consistent with US-listed equities.
The company's Growth pillar is rated Weak, reflecting ongoing challenges in scaling revenue relative to its cost base. Investors should monitor instrument placements and consumable pull-through as key indicators of commercial progress.
For the most recent quarter's results, visit Pacific Biosciences' investor relations page directly.
PACB Price History
-93.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pacific Biosciences of California, Inc.?
Based on Pacific Biosciences of California, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Pacific Biosciences do?
Pacific Biosciences designs and manufactures long-read DNA sequencing systems. Its instruments and consumables help research institutions, genome centers, pharmaceutical companies, and clinical labs analyze complex genetic data that short-read technologies struggle to resolve.
Does PACB pay dividends?
No, PACB does not currently pay a dividend. The company reinvests available resources into product development and commercial expansion rather than distributing cash to shareholders.
When does PACB report earnings?
Pacific Biosciences follows a standard quarterly reporting schedule. For confirmed dates and the most recent results, check the company's investor relations page.
Is PACB a good stock to buy?
UQS Score rates PACB as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. That combination presents notable fundamental concerns. The full pillar breakdown is available to Pro members.
Is PACB overvalued?
The UQS Valuation pillar for PACB is rated Elevated, suggesting the current market price is not well-supported by the company's underlying financial fundamentals at this stage.
What is PACB's market cap bracket?
PACB is classified as a small-cap stock, meaning its total market value is relatively modest compared to large or mega-cap peers in the healthcare and life sciences sector.
Is PACB a long-term quality investment?
From a long-term quality perspective, PACB's current UQS profile — Poor overall with Weak Quality and Moat ratings — indicates the business has not yet demonstrated the durable competitive advantages typically associated with high-quality long-term holdings. Monitoring pillar improvement over time is advisable.
What sector does PACB belong to?
PACB operates in the Healthcare sector, specifically within life sciences tools and genomics. It competes for research and clinical sequencing budgets alongside other instrument and consumable providers.
Unlock Full PACB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics behind each rating
- ✓Compare PACB against sector peers on a like-for-like basis
- ✓Track score changes as new earnings data is released
Pro Analysis
PACB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 22.7 | 2.5 | 28.0 | 31.4 | 58.8 | 0.0 | +3.6 |
| May 10, 2026 | 19.1 | 0.0 | 28.0 | 33.0 | 36.9 | 0.0 | -0.3 |
| May 8, 2026 | 19.4 | 0.0 | 28.0 | 34.3 | 36.9 | 0.0 | -4.0 |
| Apr 13, 2026 | 23.4 | 2.5 | 28.0 | 34.6 | 58.8 | 0.0 | +0.1 |
| Apr 2, 2026 | 23.3 | 2.5 | 28.0 | 34.4 | 58.8 | 0.0 | — |
PACB — Pillar Breakdown
Quality
— 2.5/100 (25%)Pacific Biosciences of California, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 31.4/100 (20%)Pacific Biosciences of California, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 58.8/100 (15%)Pacific Biosciences of California, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Pacific Biosciences of California, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 28/100 (25%)Pacific Biosciences of California, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PACB.
Score Composition
Financial Data
More Stock Analysis
How is the PACB UQS Score Calculated?
The UQS (Unified Quality Score) for Pacific Biosciences of California, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pacific Biosciences of California, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pacific Biosciences of California, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.